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Drug transporters govern the absorption, distribution, and elimination of 
pharmacologically active compounds. Members of the solute carrier (SLC) and ATP binding-
cassette (ABC) drug transporter family mediate cellular drug uptake and efflux processes, 
thereby coordinating the vectorial movement of drugs across epithelial barriers. To exert their 
physiological and pharmacological function in polarized epithelia, drug transporters must be 
targeted and stabilized to appropriate regions of the cell membrane (i.e., apical versus 
basolateral). Despite the critical importance of drug transporter membrane targeting, the 
mechanisms that underlie these processes are largely unknown. Several clinically significant 
drug transporters possess a recognition sequence that binds to PSD-95/Drosophila discs 
large/ZO-1 (PDZ) proteins. PDZ proteins, such as the Na+/H+ exchanger regulatory factor 
(NHERF) family, act to stabilize and organize membrane targeting of multiple transmembrane 
proteins including many clinically relevant drug transporters. These PDZ proteins are normally 
abundant at apical membranes, where they tether membrane-delimited transporters. NHERF 
expression is particularly high at the apical membrane in polarized tissue such as intestinal, 
hepatic, and renal epithelia, tissues important to drug disposition. Several recent studies have 
highlighted NHERF proteins as determinants of drug transporter function secondary to their role 
in controlling membrane abundance and localization. Mounting evidence strongly suggests that 
NHERF proteins may have clinically significant roles in pharmacokinetics and 
pharmacodynamics of several pharmacologically active compounds and may affect drug action 
in cancer and chronic kidney disease. For these reasons, NHERF proteins represent a novel 
class of post-translational mediators of drug transport and novel targets for new drug 
development. 
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Figure 1. Selected drug transporters expressed at epithelial barriers of intestinal enterocytes, 
hepatocytes, and kidney proximal tubule cells. ABC transporters are colored red, SLC in blue. 
ABC or SLC transporters harboring a PDZ ligand are additionally depicted with an inner dotted 
yellow circle. 
 
Figure 2. SLC drug transporter membrane topology. The prototype membrane topology of 
SLC22A family members (OCTs, OCTNs, OATs) is similar, as is SLCO for OATP family 
members. Blue cylinders represent predicted transmembrane helices. Putative N-glycosylation 
and phosphorylation sites, and important cysteine residues are shown as yellow, green, or red 
circles, respectively. 
 
Figure 3. ABC drug transporter membrane topology. The membrane topology of ABC family 
drug transporters is not uniform but differs in the number of transmembrane domains and 
nucleotide-binding domains (NBD). Red cylinders represent predicted transmembrane helices, 
and nucleotide binding-domains are depicted as yellow ovals for the ABC proteins indicated on 
the right, along with their corresponding human gene identification. 
 
Figure 4. Schematic representation of human NHERF isoforms. PDZ domains are indicated by 
the light blue rectangular boxes and ezrin-binding domains (EBD) by dark blue boxes. The 
amino acid residues that constitute the core binding-motif are noted and shown as a purple bar 
indicating their location within the respective PDZ domain. 
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Figure 5.  Model of NHERF regulation of MRP4-mediated renal proximal tubule adefovir 
secretion. Under physiological conditions (A), NHERF1 or NHERF3 (NHERF1/3) tether MRP4 to 
apical membranes. Adefovir is taken up across basolateral membranes by organic acid 
transporters OAT1 and OAT3 and exits the cell across apical membranes into the urine, The 
coordinated actions of basolateral OAT1 and OAT3 and apical MRP4 drug transporters assure 
little cytoplasmic drug accumulation. In chronic kidney disease (B), NHERF1/3 are 
downregulated. This reduces the abundance of MRP4 at apical membranes, with attendant 
cellular drug accumulation potentially leading to toxic concentrations. The illustration is based 
on recent findings (Crean et al., 2014) and unpublished observations. 
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I. INTRODUCTION 
 
 
 
Plasma membrane transport proteins play a central role in mediating the disposition or 
pharmacokinetics, i.e., absorption, distribution, and elimination of a broad spectrum of 
endogenous and exogenous compounds including pharmacologically active compounds and 
clinically used medications (Nigam, 2015). Such transporters are now acknowledged also as 
clinically significant determinants of drug response, i.e., pharmacodynamics (Konig et al., 2013). 
Although broadly expressed, drug transporters exhibit highest abundance in intestine, liver, and 
kidney; tissues important for drug disposition (Giacomini et al., 2010). Furthermore, drug 
transporters expressed at the blood-brain barrier and the placenta serve an additional protective 
role to minimize exposure of the brain and fetus, respectively, to toxic compounds. 
Solute carrier (SLC) and the ATP-binding cassette (ABC) transporters form the two 
major superfamilies of drug transporters. SLC transporters primarily mediate cellular uptake of 
drugs by facilitated diffusion or ion-coupled secondary active transport. ABC transporters 
function as primary energy-dependent active transporters and rely on the hydrolysis of ATP to 
energize cellular drug efflux. Functionally, SLC and ABC drug transporters work in concert to 
couple the vectorial movement of drugs and drug metabolites across epithelial barriers. The 
clinical impact of drug transporters in pharmacotherapy highlights the need to fully characterize 
their regulatory mechanisms (Hillgren et al., 2013). 
Epithelial cells that form the intestinal, hepatic, and renal barriers display characteristic 
apical-basolateral membrane polarity. Drug transporters that are expressed in these cells must 
be targeted and stabilized at the appropriate membrane domain (i.e., apical or basolateral) to 
elicit their physiologic and pharmacologic function (Kato, 2007). A key role of drug transporters 
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located at epithelial barriers is to limit systemic drug exposure. Oral drug absorption is 
accomplished by an array of drug transporters that are distributed throughout the intestinal 
epithelium. In the liver, transporters coordinate the hepatobiliary disposition of drugs and serve 
a principal role in biliary drug excretion. Together, intestinal and hepatic drug transporters play a 
major role in mediating drug bioavailability. Drug transporters expressed in renal proximal 
tubules move organic solutes across the proximal tubule epithelium. Drug transporters in the 
kidney are significant contributors to renal drug elimination and are involved in both secretion 
and reabsorption into and from the tubular lumen. At all of these epithelial barriers, drug 
transporters are localized to specific membrane domains, which is critical to their functional role 
in drug bioavailability, disposition, and response. Defining the mechanisms that determine drug 
transporter abundance and membrane-delimited localization is an emerging line of research. 
PDZ proteins are named for the common structural domain shared with the postsynaptic 
density protein (PSD), Drosophila disc large tumor suppressor (DlgA), and zonula occludens-1 
protein (ZO-1). In addition to their involvement in the assembly of multi-protein signaling 
complexes, PDZ domain-containing proteins also regulate membrane abundance and the 
asymmetrical sorting of proteins to specific membrane domains in polarized epithelia (Padanyi 
et al., 2010; Shenolikar et al., 2002; Shenolikar and Weinman, 2001). PDZ proteins recognize 
and bind to target proteins by specific internal and carboxy-terminal amino acid sequences, 
referred to as PDZ ligands (Songyang et al., 1997; Stricker et al., 1997). PDZ domains are 
classified based on the structural binding motif of the PDZ ligand with which they interact   
(Table 1). Class I PDZ proteins interact with ligands terminating in the sequence -X-[S/T]-X-φ, 
where X is promiscuous and φ is a hydrophobic residue, generally Leu, Ile, Val, or Met. Class II 
PDZ proteins prefer ligands terminating in -X-φ-X-φ and Class III prefer a PDZ binding motif of 
the form -[D/E]-[K/R]-X-φ. However, PDZ proteins may also recognize internal peptide 
fragments from target proteins. Residues up to 18 amino acids upstream from the carboxy-
terminus can participate in target recognition (Mahon and Segre, 2004). These non-canonical  
  3 
TABLE 1 
PDZ ligand recognition classification 
Class C-terminal consensus sequence of PDZ 
ligand‡ 
I -X-[S/T]-X-φ 
II -X- φ -X-φ 
III -[D/E]-[K/R]-X-φ 
‡ X is permissive indicating any amino acid; S/T are serine and threonine, φ hydrophobic 
residue, typically L, I, V. D/E and K/R are aspartate/glutamate, and lysine/arginine, respectively.  
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binding modes may also be important for establishing target specificities. Several clinically 
significant SLC and ABC drug transporters harbor a carboxy-terminal PDZ ligand and therefore 
may bind PDZ proteins. Mounting evidence highlights the impact of PDZ proteins in regulating 
the membrane abundance, localization, and function of a growing number of drug transporters 
(Karvar et al., 2014; Park et al., 2014; Zheng et al., 2014). 
The Na+/H+ exchanger regulatory factors (NHERFs) are a family of PDZ proteins that 
also act as mediators of drug transporter function secondary to their role in organizing drug 
transporter membrane abundance and localization. NHERF proteins alter drug transporter 
function in vitro, as well as drug absorption and disposition in vivo (Park et al., 2014). NHERF 
proteins are highly expressed at apical membranes of polarized epithelial cells of the kidney, 
intestine, and liver, where they interact with numerous drug transporters from both SLC and 
ABC superfamilies (Kato et al., 2006; Kato et al., 2004; Sugiura et al., 2011). The majority of 
reported interactions are mediated through canonical class I PDZ ligands, though interactions 
with drug transporters possessing class II and III PDZ ligands also have been described (Kato 
et al., 2004; Shimizu et al., 2011; Sugiura et al., 2008). Hence, NHERF proteins may have an 
indirect effect on drug response attributable to their influence on drug absorption and disposition 
in these important pharmacological barriers. Over the last decade, PDZ proteins have gained 
considerable attention as post-translational regulators of drug transporter function (Choi et al., 
2011; Kato et al., 2006; Miyazaki et al., 2005; Noshiro et al., 2006; Park et al., 2014; Sugiura et 
al., 2006; Sugiura et al., 2008; Sugiura et al., 2010; Sugiura et al., 2011; Wang et al., 2014; 
Zheng et al., 2014). To highlight these new findings, we review the current knowledge of drug 
transporter regulation by PDZ proteins and address the association of PDZ proteins with drug 
disposition and response in select disease states. 
  5 
II. DRUG TRANSPORTER STRUCTURE, FUNCTION, AND TISSUE LOCATION 
 
 
 
A. Solute Carrier (SLC) Drug Transporters. 
 
 
SLC drug transporters are classified into the SLC22A and SLCO gene families.1 The SLC22A 
genes include the organic anion transporters (OATs), organic cation transporters (OCTs), and 
organic carnitine transporters (OCTNs). The SLCO gene family consists of the organic anion-
transporting polypeptides (OATPs). Members of both gene families are primarily involved in 
cellular drug uptake and are abundantly expressed at the epithelium in the liver, intestine, and 
kidney (Figure. 1) (Giacomini et al., 2010). Although most SLC superfamily drug transporters 
display overlapping substrate specificities, OATs, OCTs, and OCTNs transport anions, cations, 
and zwitterions, respectively, whereas OATPs transport larger hydrophobic anions.  
 
 
 
 
                                                
1 Uppercase denotes human genes or gene products and lowercase denotes rodent genes or 
gene products 
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Figure 1 
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1. SLC22A Family. 
 
 
Transporter proteins encoded by the SLC22A gene family include, OCT1-3 (SLC22A1-3), 
OCTN1-2 (SLC22A4-5), OAT1-3 (SLC22A6-8), OAT4 (SLC22A11), and URAT1 (SLC22A12). 
The prototype membrane topology of the SLC22A family comprises 12 α-helical transmembrane 
domains (TMD), an intracellular N-terminus, a large extracellular loop between TMDs 1 and 2, 
which harbors several putative N-glycosylation sites, a large intracellular loop between TMDs 6 
and 7 that contains additional glycosylation and phosphorylation sites, and an intracellular C-
terminus (Figure. 2). Tissue expression and membrane localization of selected SLC22A drug 
transporters is summarized in Figure 1. SLC22A drug transporters and selected substrates are 
summarized in Table 2. 
 
 
 
a. Organic Cation Transporters (OCTs).   
 
 
OCT1 (SLC22A1), OCT2 (SLC22A2), and OCT3 (SLC22A3) mediate transport of organic 
cationic drugs such as metformin, histamine H2 receptor antagonists, and platinum-based 
drugs. OCT1-3 share three common functional characteristics. First, substrate transport is 
bidirectional, that is, OCTs mediate both uptake and efflux processes. Second, transport occurs 
by passive facilitated diffusion that is driven by the negatively charged intracellular membrane 
voltage. The rate of substrate uptake and efflux therefore depends upon the electrochemical 
gradient and is sensitive to changes in the membrane potential. Third, OCT-mediated transport  
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Figure 2  
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TABLE 2 
Selected Drug Transporters 
Transporter Superfamily Family Gene Name PDZ Ligand Selected 
Substrates 
OCT1 SLC SLC22 SLC22A1 --- Metformin, 
oxaliplatin 
OCT2 SLC SLC22 SLC22A2 --- Metformin, 
ranitidine, 
varinicline 
OCT3 SLC SLC22 SLC22A3 R-S-H-L Histamine, 
epinephrine 
OCTN1 SLC SLC22 SLC22A4 L-T-A-F Quinidine, 
verapamil, 
ipratropium, 
ergothioneine 
OCTN2 SLC SLC22 SLC22A5 S-T-A-F Carnitine, 
amisulpride, 
cephaloridine 
OAT1 SLC SLC22 SLC22A6 --- Lamivudine, 
acyclovir, 
ciprofloxacin 
OAT2 SLC SLC22 SLC22A7 --- Bumetanide, 
erythromycin, 
paclitaxel 
OAT3 SLC SLC22 SLC22A8 --- Furosemide, 
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bumetanide 
OAT4 SLC SLC22 SLC22A11 S-T-S-L Bumetanide, 
urate, 
methotrexate 
URAT1 SLC SLC22 SLC22A12 S-T-Q-F Urate 
OATP1A2 SLC SLCO SLCO1A2 K-T-K-L Statins, 
fexofenadine 
OATP1B1 SLC SLCO SLCO1B1 --- Statins, 
repaglinide, 
olmesartan 
OATP1B3 SLC SLCO SLCO1B3 --- Statins, 
telmisartan, 
fexofenadine 
OATP1C1 SLC SLCO SLCO1C1 E-T-Q-L Triiodothyronine 
(T3), Thyroxine 
(T4) 
OATP2B1 SLC SLCO SLCO2B1 D-S-R-V Statins, 
fexofenadine 
OATP3A1 SLC SLCO SLCO3A1 E-S-V-L Benzylpenicillin, 
vasopressin 
OATP4A1 SLC SLCO SLCO4A1 Q-S-S-V Estradiol-17β-
glucuronide 
OATP4C1 SLC SLCO SLCO4C1 --- Digoxin, 
methotrexate, 
sitagliptin 
  11 
PEPT1 SLC SLC15 SLC15A1 Q-K-Q-M Cephalexin, 
valacyclovir, 
enalapril 
PEPT2 SLC SLC15 SLC15A2 K-T-K-L Cephalexin, 
valacyclovir, 
enalapril 
MDR1 (Pgp) ABC ABCB ABCB1 --- Digoxin, 
loperamide 
BCRP ABC ABCG ABCG2 --- Statins, 
methotrexate 
MRP1 ABC ABCC ABCC1 --- Citalopram, 
methotrexate, 
Leukotriene C4 
MRP2 ABC ABCC ABCC2 S-T-K-F Olmesartan, 
methotrexate, 
etoposide 
MRP3 ABC ABCC ABCC3 --- Estradiol-17β-
glucuronide 
MRP4 ABC ABCC ABCC4 E-T-A-L Adefovir, 
topotecan, 
methotrexate 
MRP7 ABC ABCC ABCC10 D-T-R-L Docetaxel, 
paclitaxel, 
viscristine, 
vinblastine 
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is independent of sodium and pH. OCTs are expressed in the kidney, intestine, and liver, where 
they function primarily as basolateral uptake transporters. However, OCT3 may be expressed at 
both basolateral and apical membranes (Muller et al., 2005; Nies et al., 2009). For example, 
OCT3 is localized to basolateral/sinusoidal membranes of hepatocytes, and apical membranes 
of enterocytes. OCT3 is expressed in renal proximal and distal tubules but additional studies are 
needed to define OCT3 membrane localization in the kidney (Wu et al., 2000b). 
OCTs exhibit broad selectivity. Common substrates include hydrophilic, low molecular weight 
organic cations (Table 2). OCT1 and OCT2 are drug transporters of emerging clinical 
significance due to their potential influence on drug disposition and response. For example, 
OCT1 is an important factor in the pharmacotherapy of diabetes and chronic myeloid leukemia 
(CML) (Grinfeld et al., 2013; Koren-Michowitz et al., 2014; Mahrooz et al., 2014). OCT1 is 
thought to be liver-specific; it is predominately expressed on basolateral/sinusoidal membranes 
of hepatocytes and mediates drug uptake (Gorboulev et al., 1997; Zhang et al., 1997). Although 
few endogenous OCT1 substrates have been identified, evidence suggests that hepatic OCT1 
may mediate the uptake of biogenic amines such as serotonin (Boxberger et al., 2014). 
Moreover, commonly prescribed medications such as diphenhydramine, fluoxetine, imatinib, 
and verapamil, possibly inhibit OCT1-dependent serotonin uptake, a finding highlighting the 
possibility that drugs may interfere with transport and elimination of endogenous substrates at 
the transporter level. OCT2 is found exclusively in the kidney at basolateral membranes of 
proximal tubule cells, where it facilitates secretion of drugs such as cisplatin and oxaliplatin 
(Gorboulev et al., 1997; Iwata et al., 2012; Urakami et al., 2002). OCT3, in contrast to OCT1 
and OCT2, displays a much broader tissue expression pattern. In addition to expression in the 
intestine, liver, and kidney, OCT3 mRNA levels can be detected in the placenta, heart, brain, 
and skeletal muscle (Hayer-Zillgen et al., 2002). It is not known why OCT3 localizes to apical 
membranes in enterocytes but to basolateral membranes in hepatocytes. It is also not 
understood why OCT3 is capable of dual membrane localization that is tissue specific but OCT1 
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and OCT2 are restricted to basolateral membranes. Of the three OCT isoforms, only OCT3 
contains a C-terminal PDZ-ligaod (-RSHL). Therefore, the membrane localization of OCT3 may 
be determined by tissue- and domain-specific localization of PDZ proteins. 
 
 
b. Organic Cation/Carnitine Transporters (OCTNs).   
 
 
The OCTN subfamily consists of OCTN1 (SLC22A4) and OCTN2 (SLC22A5). In addition to 
their physiological role as uptake transporters for the zwitterion carnitine, members of the 
OCTNs are known also to interact with drugs such as levofloxacin, oxaliplatin, and cephaloridine 
(Hirano et al., 2008; Jong et al., 2011; Kano et al., 2009). Analogous to OCTs, OCTNs are able 
to perform bidirectional transport; however there are subtle differences in the transport 
mechanisms between OCTN1 and OCTN2. For example, OCTN1 can function as an organic 
cation uniporter or an H+/organic cation antiporter, whereas OCTN2 functions as a 
sodium/carnitine co-transporter or may perform sodium-independent cation transport 
(Grundemann et al., 2005; Ohashi et al., 2001; Tamai et al., 2004; Tamai et al., 1998; Wu et al., 
1999). Although broadly expressed in multiple tissues, OCTN subfamily members display 
preferential tissue expression. For instance, OCTN1 is predominately expressed on apical 
membranes of renal proximal tubules but is found at much lower levels in other tissues such as 
the liver, small intestine, placenta, and brain (Tamai et al., 2004; Tamai et al., 2000; Wu et al., 
2000a). OCTN2 also is expressed on apical membranes of renal proximal tubule cells but its 
expression is not limited to polarized epithelia. It is found in several organs including the heart, 
brain, liver, testis, and skeletal muscle (Tamai et al., 1998; Tamai et al., 2000). Because OCTN2 
is believed to be the major OCTN regulating serum carnitine concentrations (Nezu et al., 1999), 
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its wider expression may have evolved to ensure adequate carnitine absorption and distribution 
throughout the body. Carnitine is required for fatty acid transport in mitochondria for generation 
of metabolic energy. Underscoring its vital nature, primary carnitine deficiency, a disorder 
characterized by chronic muscle weakness, cardiomyopathy, hypoglycemia, and liver 
dysfunction, is caused by defects in OCTN2 activity (Tamai et al., 1998). The OCTN subfamily 
has been linked to other disease states as well. Several studies implicated OCTN1 and OCTN2 
in the pathophysiology of inflammatory bowl disease, diabetes, and cancer (Martini et al., 2012; 
Muoio et al., 2012; Okabe et al., 2008; Peltekova et al., 2004; Pochini et al., 2013). By virtue of 
their association with several diseases, OCTNs are studied more in the context of 
pathophysiology and less for their potential pharmacological role as mediators of drug 
absorption and disposition. Nevertheless, OCTNs are involved in transport of organic cationic 
drugs and are potential sites for drug/carnitine interactions (Ganapathy et al., 2000). OCTN1 
and OCTN2 mediate transport of drugs such as anti-psychotics, anti-hypertensives, antibiotics, 
and drugs used in the treatment of neurologic disorders (Ganapathy et al., 2000; Grube et al., 
2006; Jong et al., 2011; Nakamura et al., 2010; Urban et al., 2008). Both OCTN1 and OCTN2 
contain C-terminal PDZ ligands (-LTAF and –STAF, respectively). The role of PDZ proteins and 
OCTN membrane abundance and function is summarized in section IV.   
 
 
c. Organic Anion Transporters (OATs).   
 
 
OATs mediate the systemic removal of organic anions including drugs, toxins, and endogenous 
metabolites. OAT1-3 (SLC22A6-8), OAT4 (SLC22A11), and URAT1 (SLC22A12) are deemed 
clinically significant human OAT isoforms due to their prominent role in the kidney as mediators 
  15 
of renal secretion and thus renal drug elimination (Burckhardt, 2012; Giacomini et al., 2010). 
Historically, OATs have been the targets of pharmacological strategies to extend limited 
supplies of drugs. The classic example of OAT-targeted interventions of this manner is the 
utilization of probenecid to conserve limited supplies of penicillin during World War II. 
Probenecid, an OAT inhibitor, increases serum concentrations of penicillin by significantly 
reducing OAT dependent renal secretion, thus extending the half-life of penicillin and optimizing 
therapeutic efficacy by achieving concentrations above the minimum inhibitory concentration 
with a lower dose (Weiner et al., 1960). More recently, owing to its established inhibitory effects 
on OATs, probenecid has been suggested as an adjuvant to other medications that have been 
in short supply, such as the anti-viral drug oseltamivir (Howton, 2006). Genetic variations 
encoding different OAT isoforms are also associated with altered transporter activity and 
impaired renal handling of OAT substrates (Bleasby et al., 2005; Erdman et al., 2006; Xu et al., 
2005). For instance, genetic polymorphisms in OAT3 are associated with reduced renal 
clearance of cefotaxime, a cephalosporin antibiotic (Yee et al., 2013). Transcript variants of 
URAT1 may produce increases or decreases in renal tubular uric acid reabsorption, changes 
that result in hyperuricemia and hypouricemia respectively (Graessler et al., 2006; Wakida et al., 
2005). 
In contrast to the OCTs, OATs transport anions into cells against the negatively charged 
electrochemical gradient and therefore are energy dependent. OATs transport substrates by 
exchanging an intracellular mono- or divalent anion, typically a dicarboxylate, for uptake of an 
extracellular anion (Burckhardt, 2012). The energy expenditure that drives this process comes 
indirectly from the Na+/K+-ATPase that maintains intracellular sodium concentration at low levels 
and creates a negative intracellular voltage. This favorable electrochemical gradient drives 
sodium-coupled uptake of dicarboxylate species by the sodium-dicarboxylate co-transporter 
(NaDC3). Together, the Na+/K+-ATPase, NaDC3, and OATs cooperate to facilitate the uptake 
and removal of organic anions. OATs are heavily expressed in the kidney, where they play a 
  16 
significant role in the uptake step of renal drug accumulation. Among the OAT family, OAT1 and 
OAT3 are the most extensively studied in the context of drug transport and have been shown to 
mediate the uptake of a wide variety of structurally diverse drug classes such as anti-
hypertensive drugs, HMG Co-A-reductase inhibitors (statins), β-lactam antibiotics, H2 receptor 
antagonists, anti-neoplastic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and anti-
viral drugs (Burckhardt, 2012). However, OATs also transport multiple endogenous compounds 
and play complex physiological roles (Mandal and Mount, 2015; Nigam et al., 2015). Recent 
evidence suggests that OAT3 not only handles transport of drugs and drug metabolites, but also 
may play a role in: 1) pathways involved in the regulation of secondary metabolites, such as 
prostaglandins, steroids, and uric acid; 2) the metabolism and handling of gut microbiome 
products, as well as uremic toxins that accumulate in kidney disease; 3) handling of dietary 
flavonoids such as epicatechin; and 4) the tricarboxylic acid cycle and nucleotide and amino 
acid metabolism (Mandal and Mount, 2015; Nigam et al., 2015; Wu et al., 2013). 
OAT1 and OAT3 are exclusively located at basolateral membranes in renal proximal tubule 
cells. In the kidney, all members of the OAT family localize to basolateral membranes with the 
exception of OAT4 and URAT1. OAT4 is unique in that it is expressed only in humans and is 
located at apical membranes of renal proximal tubule cells (Babu et al., 2002; Cha et al., 2000; 
Ekaratanawong et al., 2004). OAT4 is also expressed in the placenta but is restricted to 
basolateral membranes of syncytiotrophoblasts (Cha et al., 2000). This distinctive tissue-
specific pattern of OAT4 membrane localization is similar to the dual-membrane expression 
patterns of OCT3. Like OCT3, OAT4 possesses a PDZ ligand (-STSL). Several studies suggest 
that multiple PDZ proteins may govern the membrane abundance and localization of OAT4 
(Kato et al., 2004; Miyazaki et al., 2005; Zhou et al., 2008). 
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2. SLCO Family.  
 
 
The SLCO gene family encodes the human OATPs. These proteins transport various organic 
amphiphilic compounds, the majority of which are large hydrophobic anions such as bile acids, 
steroid conjugates, and anionic peptides, as well as several drugs including statins, angiotensin 
II receptor antagonists and angiotensin converting-enzyme inhibitors (Babu et al., 2002; Cha et 
al., 2000; Ekaratanawong et al., 2004; Zhou et al., 2008). Eleven human OATPs have been 
identified to date. Selected OATPs discussed in this manuscript are summarized in Table 2. 
There are six known human OATP families. Classification of OATPs is based on their amino 
acid similarities. OATPs within the same family share ≥ 40% amino acid sequence identity and 
are assigned root names followed by a numerical designation (OATP1-6). Subfamily members 
share ≥ 60% amino acid sequence identity and are designated with a letter following the 
numerical family designation. For instance, OATP family 2 (OATP2) has two subfamilies 
(OATP2A and OATP2B). A numerical designation after the subfamily heading is assigned to 
each member of a subfamily (OATP2A1 and OATP2B1). Size differences exist across members 
of the OATP family. OATPs have an average length of 710 amino acids, but range from 643 
amino acids (OATP2A1) to 848 amino acids (OATP5A1). However, all OATPs share a similar 
predicted membrane topology that comprises 12 α-helical transmembrane domains, intracellular 
N- and C-termini, and multiple glycosylation sites within the second and fifth extracellular loop. 
The fifth extracellular loop is larger and contains multiple conserved cysteine residues that 
participate in disulfide bonds (Figure. 2). In general, OATP dependent transport involves 
bidirectional, sodium independent exchange. OATPs couple the cellular uptake of anions with 
efflux of intracellular substances such as bicarbonate, reduced glutathione, or lactate. In the 
case of OATP2B1, transport is pH sensitive but only with selective solutes such as statins 
(Kobayashi et al., 2003; Nozawa et al., 2004; Varma et al., 2011). The precise mechanism of 
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transport and how it relates to the physiological and pharmacological role of individual OATPs 
remains unclear. 
Tissue expression and membrane localization of selected SLCO drug transporters is 
summarized in Figure 1. Some members of the OATP family display broad tissue expression. 
OATP1A2, OATP2A1, OATP2B1, OATP3A1, and OATP4A1 for instance are found in multiple 
tissues including the kidney, placenta, skeletal muscle, choroid plexus, and endothelial cells of 
the blood-brain-barrier. Other OATPs exhibit a more restricted pattern. The major hepatic OATP 
isoforms include OATP1B1 and OATP1B3; OATP4C1 predominates in the kidney. Among the 
OATP family, OATP1B1, OATP1B3, OATP1A2, and OATP2B1 are considered clinically 
important determinants of pharmacokinetics due to their participation in transporting commonly 
used medications such as statins (Giacomini et al., 2010). In particular, OATP1B1 and 
OATP1B3 mediate the hepatic uptake of drugs whereas OATP1A2 and OATP2B1 mediate 
intestinal drug absorption. The extensive expression of OATPs in the intestine and liver likely 
evolved as a protective mechanism to combat inadvertent ingestion of plants or foods 
containing toxins. An additional evolutionary advantage to OATP dependent detoxification 
comes in the form of cooperativity with intestinal and hepatic metabolizing enzymes. As a 
means to provide protection against a wide spectrum of potentially harmful exogenous 
substances, intestinal and hepatic OATPs have adopted overlapping substrate specificity with 
intracellular cytochrome P450 (CYP) enzymes. Together, OATPs cooperate with CYP enzymes 
in the intestine and liver to reduce the systemic exposure of xenobiotics by exposing substrates 
to intracellular CYPs for subsequent metabolism. Evidence of this cooperative functionality is 
observed concerning the hepatic clearance of erythromycin, a commonly used probe to assess 
CYP3A function (Rivory et al., 2001). Erythromycin uptake into hepatocytes is mediated by 
OATPs (Lancaster et al., 2012; Sun et al., 2010). OATPs facilitate the uptake of erythromycin 
from the portal vein and into hepatocytes where metabolism by CYP3A occurs. (Franke et al., 
2011). Therefore, hepatic clearance of erythromycin is a function of OATP-dependent uptake 
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and CYP3A function. Although these examples illustrate OATP-CYP cooperativity, they may not 
extend to other transporters and CYP proteins.  
Although generally considered drug transporters, physiological roles of OATPs also have 
been described. Members of the OATP family are involved in the transport of bilirubin 
(OATP1B1 and OATP1B3) and thyroid hormones (OATP1C1) (Keppler, 2014; Mayerl et al., 
2014). In the liver, bilirubin metabolism and elimination is accomplished, in part, by the 
coordinated actions of OATPs and UDP glucuronosyltransferase-1 family, polypeptide-1 
(UGT1A1). Similar to the proposed mechanism of OATP-CYP cooperative functionality and drug 
metabolism, hepatic OATP1B1 and OATP1B3 facilitate the uptake of unconjugated bilirubin, 
which is followed by glucuronic acid conjugation catalyzed by intracellular UGT1A1 (Keppler, 
2014). OATPs also may be involved in transporting endogenous substances that are otherwise 
impermeant and cannot traverse the cell membrane passively and, therefore, rely on 
transporters to enter cells. OATP1C1 has been implicated recently in the transport across the 
blood-brain barrier of thyroxine (T4), the prohormone of triiodothyronine (T3), a process thought 
to be important for proper brain development (Mayerl et al., 2014). The physiological and 
pharmacological importance of renal OATPs, particularly the role of OATP4C1, is not fully 
appreciated. 
Similar to other SLC transporter families, membrane localization of OATP isoforms is not 
uniform and in some cases is tissue dependent. Although most are located on basolateral 
membranes, OATP1A2 is exclusive to apical membranes, whereas OATP2B1 displays dual 
membrane localization. In the intestine, OATP1A2 and OATP2B1 are located on the apical 
brush-border membrane, where they contribute to drug absorption. In the liver, OATP1B1, 
OATP1B3, and OATP2B1 are located on basolateral/sinusoidal membranes, where they may 
be responsible for hepatic drug uptake (Kobayashi et al., 2003; Kullak-Ublick et al., 2001; 
Tamai, 2012). OATP1A2 is also found at apical membranes in endothelial cells of the 
blood-brain barrier, hepatocytes, and renal distal tubules (Lee et al., 2005). Analogous to the 
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OCT and OAT families of drug transporters, some OATP isoforms harbor a C-terminal PDZ 
ligand and are binding partners with PDZ proteins (Kato et al., 2004; Wang et al., 2005; Zheng 
et al., 2014). Multiple PDZ proteins regulate the function of OATP1A2 (Zheng et al., 2014), 
which is discussed in section IV.  
The OATP family is gaining considerable attention due to their central role in drug 
disposition and response (Group et al., 2008; Shitara et al., 2013). This recognition is 
underscored by the importance of OATPs on statin pharmacotherapy. Statins are orally 
administrated medications and considered mainstay therapy for the treatment of 
hypercholesterolemia. In order to elicit their lipid-lowing effects, statins must be taken up into 
hepatocytes. Thus, OATPs are not only critical determinants of statin pharmacokinetics, but also 
for delivery to their site of action. Several OATPs are involved in the oral absorption and 
disposition of statins, particularly OATP1B1 (Hirano et al., 2006; Prueksaritanont et al., 2014; 
Romaine et al., 2010). All statins in clinical use are substrates for OATP1B1 (Niemi et al., 2011). 
Further, OATP1B1 polymorphisms have been shown to alter the pharmacokinetics and 
pharmacodynamics of statins including pravastatin, atorvastatin, and simvastatin (Meyer Zu 
Schwabedissen et al., 2015; Oh et al., 2013). OATP1A2 has also been recognized as important 
for drug transport and disposition. Substrates for OATP1A2 include statins, HIV-protease 
inhibitors and fexofenadine (Kullak-Ublick et al., 1998). Selected OATP substrates are listed in 
Table 2. By virtue of their expanding role in pharmacokinetics and pharmacodynamics, 
characterizing OATP regulatory mechanisms in health and disease remains an area of focus 
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3. Other SLCs (SLC15A Family). 
 
 
The SLC15A gene family encodes two human peptide transporters, PEPT1 (SLC15A1) and 
PEPT2 (SLC15A2). PEPT1 and PEPT2 function primarily as intestinal and renal peptide 
transporters, respectively. Both PEPT1 and PEPT2 are sodium independent symporters that 
couple peptide transport with the movement of H+ down its electrochemical gradient. PEPT1 is a 
high-capacity low-affinity transporter for di- and tripeptides but has negligible affinity for amino 
acids (Liang et al., 1995). PEPT1 is heavily expressed in the small intestine, where it localizes 
exclusively to the apical brush-border membranes of enterocytes (Liang et al., 1995). At the 
intestinal barrier, PEPT1 absorbs small peptides that are generated upon enzymatic breakdown 
of endogenous or ingested protein. PEPT1 also plays an important pharmacological role as a 
mediator of oral drug absorption and is a target for pro-drug design (Brandsch, 2013; Hamman 
et al., 2005; Zhang et al., 2013). Hydrophilic drug compounds that are taken orally often have 
poor bioavailability secondary to limited intestinal membrane permeability. This barrier to 
pharmacotherapy and limitation to drug design has been circumvented by exploiting intestinal 
PEPT1. As a strategy to enhance the oral bioavailability of such compounds, pro-drugs are 
formulated via amino acid esterification (Majumdar and Mitra, 2006). Chemical modifications of 
this type thus permit involvement of PEPT1 in drug uptake processes in the intestine. This 
approach has been used previously, most notably in the design of the nucleoside analog 
valacyclovir (Jacobson, 1993). Valacyclovir, a PEPT1 substrate and amino acid ester derivative 
of the active drug acyclovir, exhibits a three to five fold increase in bioavailability (Weller et al., 
1993). Intestinal PEPT1 is also involved in the absorption of other peptidomimetic drug 
compounds and pro-drugs including β-lactam antibiotics and angiotensin converting-enzyme 
inhibitors (Daniel and Adibi, 1993; Ganapathy et al., 1995; Shu et al., 2001; Sugawara et al., 
2000). PEPT2 is predominately expressed in renal proximal tubules and localizes to apical 
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membranes, where it is involved in reabsorption of di- and tripeptides from the glomerular filtrate 
(Rubio-Aliaga et al., 2003). PEPT1 is also found at apical membranes in proximal tubules, 
where it may be involved in the reabsorption of peptides that are generated by the action of 
brush border peptidases on filtered proteins. Although both PEPT isoforms are expressed in 
kidney, PEPT1 is expressed at much lower levels, and therefore the relative contribution of 
PEPT1 to renal tubule reabsorption is likely less than that of PEPT2 (Liang et al., 1995). 
Further, in contrast to PEPT1, PEPT2 is a high-affinity low-capacity transporter. This clear 
distinction in transport kinetics was described by revealing that PEPT1 and PEPT2 were 
responsible for the low-affinity (Km of 1.2 mM) and high-affinity (Km of 50 µM) transport of 
glycylsarcosine (Gly-Sar) respectively (Takahashi et al., 1998). It was later determined in 
studies comparing the contribution of PEPT1 and PEPT2 to the renal reabsorption of β-lactam 
antibiotics, that PEPT2 mediates high-affinity transport of amino β-lactam antibiotics such as 
amoxicillin, cephalexin, and cefadroxil, which contain an α-amino group, and that the 
involvement of PEPT1 is minimal in this regard (Inui et al., 2000; Takahashi et al., 1998). These 
findings strongly support that the pharmacological role of PEPT2 in the kidney might be to 
participate in reabsorption of amino β-lactam antibiotics, as well as other pharmacologically 
active compounds with similar chemical structures. Taken together, the expression pattern and 
transport kinetics of the PEPTs are not surprising if consideration is given to their physiological 
roles. The abundant expression of PEPT1, a high-capacity transporter, at the apical membrane 
in enterocytes is strategically placed to ensure adequate dietary protein absorption. Conversely, 
the expression of PEPT2, a high-affinity transporter with specific substrate affinities, at apical 
membranes in renal proximal tubules cells facilitates tight control of compounds that undergo 
renal elimination. The pharmacological implications of PEPT1 and PEPT2 function may be to 
mediate the intestinal absorption and renal reabsorption of drugs respectively.  
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Both PEPT isoforms diverge in their substrate affinity and transport capacity but share 
substrate specificity, transport mechanisms, and are exclusively located at apical membranes 
(Daniel and Adibi, 1993; Ganapathy et al., 1995; Leibach and Ganapathy, 1996; Liang et al., 
1995; Lin et al., 1999; Saito et al., 1996). The mechanism for the exclusive apical localization of 
the PEPTs in the intestine and kidney is not clear. However, PEPT1 (-QKQM) contains a class 
III PDZ ligand whereas PEPT2 (-KTKL) contains a class I PDZ-ligand and both PEPT1 and 
PEPT2 interact with PDZ proteins (Kato et al., 2004). Localization of PEPT1 at apical 
membranes in enterocytes from nherf3-/- mice is almost completely absent indicating NHERF3 
may play a role in PEPT1 regulation (Sugiura et al., 2008). Although multiple PDZ proteins have 
been shown to influence PEPT2 function, the role of PDZ proteins on PEPT1 function is less 
understood (Boehmer et al., 2008; Kato et al., 2004; Noshiro et al., 2006). These observations 
suggest that PDZ regulation of drug transporter membrane abundance may not solely depend 
on the presence of a class I PDZ-ligand. This may indicate that PDZ-drug transporter 
interactions are mediated through other binding motifs or facilitated by other cytoplasmic 
adapter proteins. A detailed analysis on the differences in PDZ regulation of PEPT1 and PEPT2 
in the intestine and kidney respectively, will address this disparity and may provide important 
clues lending to the complexity of PDZ function. 
 
 
B. ATP Binding-Cassette (ABC) Drug Transporters 
 
 
The ABC superfamily represents the largest family of membrane transporters, comprising 49 
members divided into 7 subfamilies (ABCA-ABCG) (Table 2). Members of subfamilies B, C, and 
G are the best studied in the context of drug transport and disposition. Specifically, the multidrug 
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resistance protein (MDR1, ABCB1), multidrug resistance-associated proteins (MRPs, ABCCs), 
and breast cancer resistance protein (BCRP, ABCG2) are clinically significant mediators of 
multi-drug resistance and response (Giacomini et al., 2010; Hillgren et al., 2013; Zamek-
Gliszczynski et al., 2012). Drug resistance is a clinical problem in the treatment of many types of 
cancer. Resistance to several anti-cancer agents is caused, in part, by increased ABC drug 
transporter function (Kathawala et al., 2014). In tumors, ABC drug transporters actively extrude 
anti-cancer agents and prevent intracellular drug accumulation resulting in poor drug response 
(Kim et al., 2014). In a similar manner, ABC drug transporters limit the systemic exposure of 
drugs and drug metabolites by preventing drug absorption and promoting drug elimination at 
anatomical barriers such as intestinal, hepatic, and renal epithelia, tissues where ABC drug 
transporter expression is high. The mechanism of transport is similar among all members in that 
they require ATP hydrolysis to energize cellular drug efflux. Most members share a membrane 
topology consisting of 12 hydrophobic TMDs that are divided into two distinct clusters, each 
containing six TMDs, and each with its own nucleotide binding-domain (NBD) (Figure. 3). 
MRP1, MRP2, MRP3, MRP6, and MRP7 harbor an additional cluster consisting of five TMDs 
near the N-terminus (Figure. 3.) (Choi and Yu, 2014). BCRP is unique among the ABC family in 
that it contains only six TMDs and one NBD (Figure. 3). For that reason BCRP is considered a 
“half-transporter.” ABC drug transporters expressed in the intestine, liver, and kidney mediate 
the cellular efflux of a vast array of structurally diverse drugs from several drug classes 
including, anti-cancer drugs, antibiotics, statins, and HIV protease inhibitors, among many 
others (Cascorbi, 2011; Keppler, 2011; Mao and Unadkat, 2014). ABC drug transporters are 
also the molecular basis for clinically significant drug-drug interactions, which lead to changes in 
serum drug concentrations and consequently drug response (Konig et al., 2013). In order to limit 
drug exposure by promoting drug elimination in polarized epithelia, ABC drug transporters must 
be targeted to the membrane domain that complements this function, which in many cases is 
the apical membrane facing a luminal space. ABC drug transporters facilitate drug extrusion into  
  25 
 
 
 
 
 
 
 
Figure 3  
  26 
bile (from hepatocytes), urine (from renal proximal tubule cells), and the intestinal lumen (from 
enterocytes). Tissue expression and membrane localization of selected ABC drug transporters 
is summarized in Figure 1. ABC drug transporters and a list of selected substrates are 
summarized in Table 2. 
 
 
1. MDR1 (ABCB1).  
 
 
The ABCB1 gene encodes MDR1, commonly referred to as P-glycoprotein (Pgp). Pgp was one 
of the first members of ABC drug transporters to be identified and has been well studied since it 
was first cloned and characterized nearly four decades ago (Juliano and Ling, 1976). Pgp is 
extensively distributed throughout the body with highest expression in epithelial cells with 
excretory roles such as intestinal, hepatic, and renal epithelia (Thiebaut et al., 1987). It is also 
expressed in epithelial cells lining the pancreatic ducts, as well as in endothelial cells of the 
blood-brain barrier (Beaulieu et al., 1997; Thiebaut et al., 1987). Pgp specifically localizes to 
apical membranes. The location of Pgp at the luminal surface supports its physiological role to 
protect susceptible organs from a broad array of exogenous compounds and environmental 
toxins including an equally diverse list of drugs and drug metabolites (Padowski and Pollack, 
2010; Staud et al., 2010). Pgp actively extrudes intracellular substrates in an ATP-dependent 
manner and prevents tissue accumulation by promoting excretion. Pgp substrates include 
multiple drugs from structurally diverse classes such as immunosuppressants, antibiotics, 
statins, β-blockers, anti-cancer drugs, and the cardiac glycoside digoxin, among many others 
(Cascorbi, 2011; Cascorbi and Haenisch, 2010; Fromm, 2004).  
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Pgp is limited to apical membranes. The mechanism of its specific membrane domain 
localization is unknown. Pgp does not harbor a C-terminal PDZ ligand and there is no evidence 
for interaction with PDZ proteins. Its homolog, the cholesterol efflux regulatory protein (ABCA1), 
contains a PDZ ligand (-ESYV) and is regulated by PDZ proteins (Okuhira et al., 2010). Though 
Pgp appears to not interact with PDZ proteins directly, radixin, a cytoskeletal adapter protein 
that interacts with PDZ proteins, plays an important role in regulating intestinal Pgp localization 
and function (Yano et al., 2013). This implies that PDZ proteins may be involved in regulating 
Pgp localization indirectly via interactions with radixin or other cytoskeletal adapter proteins 
such as ezrin or moesin. Regulation of Pgp function secondary to membrane abundance and 
localization is not well studied and may be another example of higher order complexity 
regarding PDZ function.  
Pgp is widely acknowledged as a clinically significant mediator of pharmacokinetics and 
pharmacodynamics due to its high expression in tissues important for drug disposition and well-
established list of substrates and inhibitors (Giacomini et al., 2010). Pgp is implicated in several 
clinically significant drug-drug interactions. The quindine-digoxin interaction is a classic example 
of a Pgp mediated drug-drug interaction (Bigger and Leahey, 1982). The anti-arrhythmic drug 
quinidine is an established Pgp inhibitor. When co-administered with the cardiac glycoside 
digoxin, a Pgp substrate, patients are at risk for digoxin-induced toxicity including the 
development of cardiac arrhythmias (Gessman et al., 1983). This adverse drug event is partially 
attributed to an increase in the systemic exposure of digoxin secondary to impaired Pgp 
dependent renal elimination (De Lannoy et al., 1992). Other clinically significant Pgp interactions 
have been documented (Aszalos, 2007). For these reasons, regulatory agencies such as the 
Food and Drug Administration (FDA) and European Medicines Agency (EMA) suggest that all 
new drug candidates be screened for in-vitro Pgp substrate and inhibition liability. 
  28 
2. MRPs (ABCCs) 
 
 
The MRP family of drug transporters is encoded by the ABCC gene subfamily. The MRP family 
consists of 9 proteins (MRP1-9). Analogous to other members of the ABC superfamily of drug 
transporters, MRPs mediate cellular drug efflux and play a central role in protecting tissues from 
accumulation of toxic compounds. MRPs are also responsible for transporting several 
endogenous physiological molecules, illustrating that their function is not purely 
pharmacological. For example, MRP1 mediates the transport of reduced and oxidized 
glutathione and the pro-inflammatory mediator, cysteinyl leukotriene C4 (Cole, 2014). The 
physiological role of MRP4 is to regulate intracellular concentrations of cyclic nucleotides, such 
as cAMP and cGMP, by functioning as a nucleotide efflux transporter. MRP4 regulation of 
cAMP has recently been implicated in the mechanism of drug-induced diarrhea, and in fibroblast 
cell migration (Moon et al., 2015; Sinha et al., 2013). In addition to their pharmacological role as 
mediators of drug disposition, dysfunctional MRPs are responsible for the development of 
pathophysiological conditions. For example, sequence variations that result in loss of functional 
MRP2 and MRP6 are the molecular basis for Dubin-Johnson syndrome (DJS) and 
pseudoxanthoma elasticum (PXE), respectively (Bergen et al., 2007; Kartenbeck et al., 1996; 
Toh et al., 1999). DJS is characterized by dysfunctional hepatic secretion of conjugated bilirubin 
into the bile. The loss of functional MRP2 on the apical/canalicular membrane of hepatocytes 
impairs biliary excretion of conjugated bilirubin, which results in elevated serum concentrations 
of bilirubin and the development of DJS (Devgun et al., 2012). PXE is characterized by 
mineralization and eventual degradation of elastic fibers in connective tissue, which can lead to 
loss of vascular tone and premature arteriosclerosis (Li et al., 2009). Although the molecular 
pathologies of PXE are still unclear, mutations in MRP6 cause PXE (Bergen et al., 2007). The 
physiological MRP6 substrates that are involved in the development of PXE remain unknown. In 
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accordance with their functional role, MRPs are prominently expressed at anatomical barriers, 
with high expression in the intestine, liver, kidney, and blood-brain barrier.  
The MRPs display overlapping substrate specificity for many endogenous and 
exogenous lipophilic organic anions. MRP drug substrates include statins, angiotensin II 
receptor antagonists, anti-viral drugs, and chemotherapeutic agents (Keppler, 2011). Within the 
MRP family, MRP2 and MRP4 are deemed the most clinically significant to drug development 
due to their established influence on drug disposition and expanding list of drug substrates 
(Giacomini et al., 2010; Hillgren et al., 2013; Zamek-Gliszczynski et al., 2012). Several 
commonly used medications are substrates for MRP2 dependent transport including 
methotrexate, olmesartan, and etoposide (Gerk and Vore, 2002). In the kidney, MRP4 plays a 
principal role in the renal luminal efflux of acyclic nucleotide reverse transcriptase inhibitors such 
as adefovir and tenofovir (Imaoka et al., 2007). An important clinical limitation to the usage of 
adefovir and tenofovir is the development of nephrotoxicity, which has been proposed to be 
partially attributable to a reduction in MRP4 dependent renal secretion (Izzedine et al., 2005). 
MRP2 and MRP4 seem to be responsible for drug transport, whereas other members of the 
MRP family are involved in transport of endogenous substrates. Although both MRP2 and 
MRP4 are expressed in the liver and kidney, MRP2 is considered the major hepatic isoform 
whereas MRP4 predominates in the kidney. Interestingly, both hepatic and renal MRP2 localize 
to apical membranes, whereas kidney MRP4 is found at apical membranes but at basolateral 
surfaces in hepatocytes. The mechanism responsible for the difference in membrane 
localization of MRP4 in the liver versus the kidney is not known. Both MRP2 (-STKF) and MPR4 
(-ETAL) contain C-terminal PDZ ligands. Multiple PDZ proteins regulate MRP2 and MPR4 
function secondary to preservation of membrane abundance and organization of membrane 
localization (Hoque et al., 2009; Karvar et al., 2014; Park et al., 2014). In addition, members of 
the ERM family, such as radixin and ezrin, have been shown to regulate MRP2 function. Radixin 
selectively modulates the functional expression of hepatic MRP2, but not other MRP isoforms 
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(He et al., 2012; Kikuchi et al., 2002). Other studies show that both radixin and ezrin are 
required for MRP2 apical membrane localization (Yang et al., 2007). The role of radixin and 
ezrin in targeting MRP2 to apical membranes is believed to be secondary to preventing 
internalization (Kojima et al., 2008; Rost et al., 2008; Saeki et al., 2011; Yang et al., 2007). 
Considering PDZ proteins are known to interact with the ERM family, these observations may 
indicate that MRPs are subject to tissue specific PDZ regulation dictated by distinct patterns of 
tissue expression and co-localization of PDZ proteins with selected ERM proteins. Therefore, 
tissue-specific ERM proteins may influence the non-redundant physiological and 
pharmacological roles of PDZ proteins in different tissues. Determining how PDZ proteins 
cooperate with cytoskeletal adapter proteins to regulate membrane abundance, localization, and 
function of target proteins in different tissues, such as drug transporters, may address these 
issues. 
 
 
3. BCRP (ABCG2).  
 
 
Breast cancer resistance protein (BCRP) is the second member of the G subfamily of ABC drug 
transporters and is encoded by ABCG2. BCRP was originally identified in several breast cancer 
cell lines, where it confers resistance to multiple anti-cancer drugs. (Dietel et al., 1990; Futscher 
et al., 1994; Kellner et al., 1997; Nakagawa et al., 1992; Taylor et al., 1991). It was later cloned, 
characterized, and assigned to the G subfamily of ABC drug transporters (Doyle et al., 1998). 
BCRP contains only 6 TMDs and one NBD and thus is considered a half transporter because it 
diverges from the prototypical membrane topology of other ABC drug transporters. Recent 
evidence shows that BCRP forms homodimers or homooligomers in intact cells (Ni et al., 2010). 
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Covalent linkages mediated by cysteine residues in the third extracellular loop are believed to 
be responsible for BCRP dimerization (Shigeta et al., 2010). However, dimerization is not a 
requirement for BCRP function (Kage et al., 2005; Shigeta et al., 2010). The expression pattern 
of BCRP complements its role as an efflux drug transporter. BCRP is highly expressed at the 
luminal surface of intestinal and hepatic epithelia where it attenuates intestinal drug absorption 
and promotes biliary drug excretion (Hillgren et al., 2013). The highest expression of BCRP is 
detected in placental tissue, specifically on apical syncytiotrophoblast membranes. Other 
tissues with high expression of BCRP include the blood-brain barrier, testis, and lactating 
mammary tissue (Jani et al., 2014). In the kidney, BCRP localizes to apical membranes of 
proximal tubule epithelial cells, however its level of expression is less compared to the intestine 
and liver (Mao and Unadkat, 2014). BCRP transports a broad array of both endogenous and 
exogenous compounds, including several marketed drugs such as anti-cancer agents, 
nucleoside analogs, and statins. A list of selected BCRP substrates is summarized in Table 2. 
Recent clinical pharmacogenetic studies have emphasized the importance of BCRP to 
drug disposition and response, which has prompted the FDA and EMA to recommend that all 
investigational new drugs be tested for BCRP substrate and inhibitor liability, except for 
substrates that fall into biopharmaceutical classification system 1; drugs with high solubility and 
high permeability. Loss of function BCRP polymorphisms that result in decreased drug 
clearance and increased drug exposure and toxicity have been reported. For example, in 
carriers of BCRP polymorphisms, the systemic exposure of several drugs such as atorvastatin, 
rosuvastatin, sunitinib, and sulfasalazine is significantly increased (Giacomini et al., 2013; Lee 
et al., 2015; Mizuno et al., 2012). In the case of sunitinib, carriers of BCRP polymorphisms also 
experience a higher incidence of sunitinib-induced toxicity (Mizuno et al., 2012). In addition to 
altering pharmacokinetics and pharmacodynamics, BCRP polymorphisms are associated with 
disease states such as Alzheimer’s disease and gout (Feher et al., 2013; Matsuo et al., 2011b; 
Takada et al., 2014). The association between BCRP and these disease states is hypothesized 
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to be secondary to BCRP dependent handling of amyloid beta in Alzheimer’s disease and uric 
acid in patients with gout (Abuznait and Kaddoumi, 2012; Matsuo et al., 2011a; Matsuo et al., 
2011b). 
BCRP membrane location in polarized cells is restricted to apical membranes. The 
mechanism that underlies the restricted apical membrane localization of BCRP has yet to be 
defined. Despite the fact that BCRP (-KKYS) does not harbor a PDZ ligand, NHERF3 regulates 
intestinal BCRP function and plays an important role in localizing BCRP to apical membranes in 
enterocytes (Shimizu et al., 2011). NHERF3 also regulates intestinal PEPT1, which harbors a 
class III PDZ ligand (-QKQM) (Shimizu et al., 2011; Sugiura et al., 2008). These observations 
suggest that the interaction between NHERF3 and BCRP differs from those of other drug 
transporters, which interact with NHERFs via a canonical PDZ ligand. The mechanism of 
NHERF3 regulation of BCRP may involve the presence of a non-canonical PDZ-binding motif. 
The NHERF3-interacting binding sequence in BCRP is unclear. Due to its extensive tissue 
distribution, expanding list of drug substrates, and association with altered pharmacokinetics 
and pathophysiology, BCRP has been recognized as a clinically relevant drug transporter of 
emerging importance. 
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III. TISSUE AND CELLULAR LOCALIZATION OF PDZ PROTEINS 
 
 
 
PDZ domains are the most abundant protein-protein interaction modules in humans 
(Feng and Zhang, 2009; Ponting et al., 1997). Canonical PDZ domains consist of 80 to 90 
amino acid residues that form six β-stands (βA to βF) and two α-helices (αA and αB) that are 
arranged in a three-dimensional globular structure (Karthikeyan et al., 2001). Binding of a 
protein ligand to the PDZ domain occurs within a hydrophobic binding pocket that is created by 
the βB strand, the αA helix, and the loop connecting the αA and βB strands. This carboxylate-
binding loop contains a GLGF core motif or a related sequence such as GYGF, as is the case 
with the NHERF family of PDZ proteins (Ponting et al., 1997). PDZ domains interact with target 
proteins via specific internal or carboxy-terminal amino acid residues, commonly referred to as 
PDZ ligands. Carboxy- terminal PDZ ligands are a short stretch of amino acids approximately 
three to four residues in length, though upstream sequences affect affinity and specificity of 
binding. The amino acid sequence that comprises the PDZ ligand is conventionally numbered 
starting from the last amino acid at the extreme carboxy-terminus and is assigned position zero 
(P0).  
PDZ recognition motifs are grouped into three classes (Class I-III) according to the 
consensus sequence of the PDZ ligand for which they bind. Table 1 summarizes the 
classification of PDZ ligands. Binding specificity among the three classes is determined, in part, 
by the interaction between the first amino acid residue in the βB-helix of the PDZ domain and 
the amino acid at position two (P2) of the PDZ ligand in the target protein. There are over 150 
PDZ domain-containing proteins and more than 250 distinct PDZ domains in the human 
proteome. Individual PDZ proteins may contain multiple PDZ domains as well as other 
  34 
interaction modules such as ezrin-binding domains (EBDs). PDZ proteins lack intrinsic catalytic 
activity and therefore function primarily as scaffold proteins, where they execute a range of 
biological functions that include establishing and maintaining cellular polarity, assembling multi-
protein signaling complexes, and anchoring transmembrane proteins, including transporters, to 
the actin cytoskeleton via interactions with the ezrin/radixin/moesin/merlin (ERM) family of 
adapters (Georgescu et al., 2014; Ponting et al., 1997; Wang et al., 2010; Wang et al., 2007; 
Wang et al., 2012; Zheng et al., 2014).  
NHERF proteins are the most well studied PDZ proteins that are expressed in polarized 
epithelia. The NHERF family consists of four structurally related proteins (NHERF1-4)     
(Figure. 4). NHERF1 and NHERF2 contain two tandem non-identical PDZ domains and an 
EBD, whereas NHERF3 and NHERF4 have four PDZ domains but lack an EBD (Seidler et al., 
2009). NHERF proteins play an important role in organizing signaling complexes, controlling 
apical membrane trafficking, and coupling apical membrane transporters and receptors with 
other PDZ targets (Georgescu et al., 2014; Klenk et al., 2010; Wang et al., 2007). Although 
NHERF isoforms share these common functional characteristics, they perform distinct 
physiological functions. For example, both NHERF1 and NHERF3 are important for phosphate 
homeostasis, yet in nherf1-/- and nherf3-/- mice, only nherf1-/- mice exhibit prominent phosphate 
wasting, suggesting that NHERF1 and NHERF3 play different physiologic roles (Giral et al., 
2011; Kocher et al., 2003; Shenolikar et al., 2002). NHERF proteins also exhibit differential 
tissue expression. NHERF1 and NHERF2, for instance, are abundantly expressed and widely 
distributed, with NHERF2 displaying a more restricted tissue distribution compared to NHERF1. 
NHERF1 is highly expressed on the apical aspect of polarized epithelia in the kidney, liver, and 
placenta (Reczek et al., 1997). NHERF1 also is found in regions of the gastrointestinal tract 
(small intestine and colon), gastric parietal cells, and brain (Reczek et al., 1997; Weinman et al., 
1995). Although NHERF2 is co-expressed with NHERF1 in the kidney, its distribution within the 
kidney differs. NHERF1 is found in proximal tubules, whereas NHERF2 is expressed in the  
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glomeruli, collecting duct, and throughout the renal vasculature and is absent from the proximal 
tubule. The highest expression of NHERF2 is in lung, including pulmonary alveoli. NHERF3 is 
expressed at the brush-border membrane of proximal tubule cells, the intestinal epithelium, and 
is also found in the liver (Custer et al., 1997; Gisler et al., 2001; Kocher et al., 1998). NHERF1 
and NHERF3 predominantly localize to the apical aspect of polarized epithelia, whereas the 
localization of NHERF2 is variable including both apical membranes and a diffuse sub-cellular 
cytosolic distribution among different tissues. NHERF4 represents the isoform with the most 
restricted tissue distribution. Significant levels of NHERF4 are found in the kidney and 
gastrointestinal tract. Within these tissues, NHERF4 is localized to the apical surface and sub-
apical regions throughout the cytoplasm (Donowitz et al., 2005; Gisler et al., 2001). 
NHERF proteins can form homo- and heterodimers or undergo oligomerization. 
Dimerization is thought to be mediated either by intermolecular interactions between PDZ 
domains or by an intramolecular head-to-tail interaction between the carboxy-terminus and a 
PDZ domain within the same protein, as is the case with NHERF1 (Lau and Hall, 2001; Morales 
et al., 2007; Shenolikar et al., 2001). Head-to-tail dimerization of NHERF1 is mediated by the 
interaction between the carboxy-terminus, which itself serves as a PDZ-ligand (-FSNL), with 
PDZ2 (Morales et al., 2007; Wang et al., 2012). Although the biological significance of NHERF 
dimerization is not fully appreciated, a recent study showed that heterodimerization of NHERF2 
and NHERF3 is required for the inhibition of Na+/H+ exchanger-3 by carbachol (Yang et al., 
2014). The formation of a large scaffolding complex comprising multiple NHERF isoforms 
because of dimerization may give rise to an elaborate network of cytoplasmic scaffold proteins. 
Formation of such a complex may dictate unique tissue-specific NHERF function. Elucidating 
the physiological importance of NHERF dimerization as it relates to function may aid in our 
understanding of the in-vivo roles of the NHERF family.  
Despite the structural similarities in PDZ domains among the NHERF family, target 
proteins that harbor PDZ ligands, including drug transporters, display different affinities for 
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NHERF isoforms (Hoque and Cole, 2008; Park et al., 2014; Wang et al., 2010). Such 
differences in affinity may partially explain the non-redundant physiological functions of the 
NHERF family, as well as the fact that several tissues express multiple NHERF isoforms (Voltz 
et al., 2001). Additionally, due to the fact that NHERF proteins can form homo- and 
heterodimers, some NHERF isoforms may operate independently, whereas other physiological 
processes may require NHERF cooperativity. In the latter scenario, NHERF proteins would bind 
to target proteins directly via one PDZ domain, reserving the remaining PDZ domain(s) to 
interact with other NHERF isoforms that in turn are responsible for anchoring the entire multi-
protein complex to the actin cytoskeleton through interactions with the ERM family. Further 
studies are needed to determine the physiological and potential pharmacological relevance of 
NHERF dimerization, cooperativity, and regulation of drug transport. 
Given that NHERF expression parallels that of drug transporters and that several drug 
transporters have been identified as NHERF binding partners, these proteins constitute a novel 
class of post-translational mediators of drug transport. For this reason, among all PDZ proteins, 
the NHERF proteins are the most extensively studied in the context of drug transporter 
regulation. 
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IV. ROLE OF PDZ PROTEINS IN REGULATION OF CELL MEMBRANE ABUNDANCE, 
LOCALIZATION, AND FUNCTION OF DRUG TRANSPORTERS 
 
 
 
The widely acknowledged clinical significance of drug transporters has led to a surge in 
studying their regulatory mechanisms. Recently, the mechanisms that underlie drug transporter 
membrane organization and abundance has gained considerable interest. In order to coordinate 
the vectorial movement of drugs across polarized epithelia, drug transporters must be sorted 
and stabilized to the appropriate membrane domain. By virtue of the fact that drug transporters 
display unique tissue-specific apical or basolateral membrane localization, domain organization 
is not random. If the mechanisms that dictate membrane organization and stability are faulty, 
drug transporters may localize to the wrong membrane domain or display decreased membrane 
abundance. The consequences of faulty membrane targeting could result in an overall reduction 
in transporter function, which may then alter the pharmacokinetics and pharmacodynamics of 
drugs that utilize transporter pathways for elimination. The mechanism of NHERF1 dependent 
renal phosphate excretion, secondary to its role in stabilizing the sodium phosphate co-
transporter-2a (NaPi-2a) to the apical membrane in renal proximal tubule cells, best illustrates 
this. In the absence of NHERF1, the membrane abundance of NaPi-2a decreases, preventing 
phosphate reabsorption from the glomerular filtrate and thus promoting renal phosphate 
excretion (Shenolikar et al., 2002). Exploring NHERF in the setting of drug transport may 
address disparities surrounding drug transporter function and drug response. Emerging 
evidence has shown that PDZ proteins, namely the NHERF family, play a critical role in the 
localization, stabilization, and functional regulation of select SLC and ABC drug transporters 
(Table 3) (Sugiura et al., 2011).  
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TABLE 3 
NHERF-dependent regulation of drug transporter function 
Transporter NHERF 
Isoform 
Experimental 
Model 
Substrate Transporter 
Function 
Citation 
OCTN2 NHERF3 
NHERF4 
HEK293 Carnitine Increase (Kato et al., 2005) 
(Watanabe et al., 2006) 
Octn2 Nherf3 Nherf3-/- mice Carnitine Decrease (Sugiura et al., 2008) 
OAT4 NHERF1 
NHERF3 
HEK293 
LLC-PK1 
Estrone-3-Sulfate Increase (Miyazaki et al., 2005) 
(Zhou et al., 2008) 
URAT1 NHERF3 HEK293 Urate Increase (Anzai et al., 2004) 
OATP1A2 NHERF1 
NHERF3 
HEK293 Estrone-3-Sulfate Increase (Zheng et al., 2014) 
Oatp1a1 Nherf3 Nherf3-/- mice Estrone-3-Sulfate Increase (Sugiura et al., 2010) 
PEPT2 NHERF2 Xenopus 
oocytes 
Gly-Gly Increase (Boehmer et al., 2008) 
PEPT2 NHERF3 HEK293 Gly-Sar Increase (Noshiro et al., 2006) 
(Sugiura et al., 2006) 
Pept1 Nherf3 Nherf3-/- mice Cephalexin Decrease (Sugiura et al., 2008) 
MRP2 NHERF1 WIF-B CMFDA Increase (Karvar et al., 2014) 
MRP4 NHERF1 HeLa 6-mercaptopurine, 
9-[2-
(phosphonylmethoxy) 
ethyl]-adenine 
Decrease (Hoque and Cole, 2008) 
MRP4 NHERF3 HEK293 Adefovir Increase (Park et al., 2014) 
Mrp4 Nherf3 Nherf3-/- mice Adefovir Decrease (Park et al., 2014) 
Bcrp Nherf3 Nherf3-/- Cimetidine Decrease (Shimizu et al., 2011) 
Uppercase denotes human genes or gene products and lowercase denotes rodent genes or 
gene products.  
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A. SLC Drug Transporters 
 
 
1. OCTNs 
 
 
Although the molecular mechanisms of membrane targeting of the OCT and OCTN family are 
not well characterized, NHERF2, NHERF3, and NHERF4 have been shown to interact with 
and/or directly regulate OCTN2 function via modulating membrane abundance (Kato et al., 
2005; Sugiura et al., 2006; Sugiura et al., 2008; Watanabe et al., 2006). A pull-down study using 
recombinant C-terminal proteins identified an interaction between apically localized OCTN1 and 
OCTN2 with both NHERF2 and NHERF3, but not with OCT1 and OCT2, which in contrast, do 
not harbor PDZ ligands and exclusively localize to basolateral membranes (Kato et al., 2005). 
Additional studies revealed that the interaction required the presence of the last four amino 
acids of OCTN1 and OCTN2 (-LTAF and -STAF respectively), both of which are class-I PDZ 
ligands. The interaction of NHERF3 with the C-terminus of OCTN2 was confirmed in a pull-
down study using kidney brush-border membrane vesicles. Subsequent immunohistochemical 
analysis revealed that NHERF3 and OCTN2 co-localize in mouse kidney brush border 
membranes. Further, NHERF3 increased OCTN2 mediated uptake of carnitine, a well-
established OCTN2 probe substrate. This result could be explained by a 6-fold increase in 
carnitine transport capacity in-vitro. Modulation of OCTN2 function by NHERF3 was not 
observed upon deletion of the last four amino acids of OCTN2 (-STAF), supporting that these 
two proteins interact directly via the PDZ ligand of OCTN2 (Kato et al., 2005). An in-vivo study 
performed in nherf3-/- mice found that absorption of carnitine was decreased compared to wild-
type mice (Sugiura et al., 2008). Immunohistochemical analysis revealed that the apical 
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localization of intestinal Octn2 was reduced in nherf3-/- mice compared to wild-type mice 
(Sugiura et al., 2008). Collectively, these studies suggest a role for NHERF3 in regulating 
OCTN2 membrane abundance and function in the kidney and intestine. NHERF2 may have a 
similar role.   
Co-expression of OCTN2 and NHERF4 in HEK293 cells also increased the uptake of 
carnitine (Watanabe et al., 2006). Subsequent kinetic analysis revealed a 2-fold increase in 
transport capacity but a minimal effect on carnitine specificity for OCTN2, suggesting that the 
increase in OCTN2 function was not due changes in carnitine affinity, but rather a greater 
number of OCTNs involved in transport. Further, upon deletion of the last four amino acids in 
OCTN2 (-STAF), the effect of NHERF4 on OCTN2 was abolished (Watanabe et al., 2006), 
signifying that the mechanism is dependent on the presence of the PDZ ligand. However, these 
results were not observed when NHERF4 was co-expressed with OCT3 or OCTN1, despite the 
fact that both OCT3 and OCTN1 harbor class-I PDZ ligands (-RSHL and -LTAF respectively). 
These data indicate that NHERF4 might operate by a mechanism that is reliant on structural 
characteristics other than the existence of a PDZ ligand alone. 
Taken together, NHERF proteins may differentially modulate OCTN function secondary 
to preservation of membrane abundance. These data also point to an uncharacterized NHERF 
mechanism that operates independent of a PDZ ligand. This hints to involvement of other 
cytoplasmic adaptor/scaffold proteins or non-canonical binding motifs affecting NHERF binding 
affinities and thus function. Given that OCTNs have described roles in pharmacokinetics, 
pharmacodynamics, and pathophysiology, characterizing NHERF mediated OCTN function may 
lead to a more detailed mechanistic explanation of the pharmacological and pathophysiological 
role of OCTNs. 
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2. OATs 
 
 
The OATs play clinically important roles in the disposition of several pharmacologically active 
compounds as well as many endogenous substances. OAT4 and URAT1 are highly expressed 
in the kidney and are exclusively found at apical membranes, whereas other renal OAT isoforms 
(OAT1-3) are found at the basolateral membrane (Burckhardt, 2012). Among the OAT family, 
OAT4 and URAT1 contain class-I PDZ ligands (-STSL and -STQF respectively) and have been 
shown to be binding partners with NHERF1 and NHERF3. Evidence suggests that NHERF1 and 
NHERF3 play a role in regulating OAT4 and URAT1 function (Anzai et al., 2004; Miyazaki et al., 
2005; Zhang et al., 2010a; Zhou et al., 2008). Yeast two-hybrid studies and surface plasmon 
resonance confirmed OAT4 binds both NHERF1 and NHERF3, and that the interaction is 
mediated by the C-terminal region of OAT4 and the PDZ1 domain of NHERF1, and both PDZ1 
and PDZ4 domains in NHERF3 (Miyazaki et al., 2005). The association of OAT4 with NHERF1 
and NHERF3 depends on the presence of the C-terminal PDZ ligand of OAT4 (-STSL). Further, 
association of OAT4 with NHERF1 or NHERF3 enhanced transport of estrone-3-sulfate, an 
established OAT4 probe substrate, in HEK293 cells. Upon deletion of the OAT4 PDZ ligand, this 
functional effect was abolished (Miyazaki et al., 2005). These data indicate that NHERF1 and 
NHERF3 may affect OAT4 function through interactions mediated by specific PDZ domains. 
The effect of NHERF proteins on OAT4 function may be tissue specific (Zhou et al., 
2008). In a comparison of NHERF mediated OAT4 function in LLC-PK1 versus BeWo cells, a 
kidney and placental cell line respectively, NHERF1 and NHERF3 only enhanced OAT4 
dependent estrone-3-sulfate uptake in LLC-PK1 cells but not BeWo cells. This suggests that the 
effect of NHERF1 and NHERF3 may be cell or tissue specific. These results further support the 
hypothesis that NHERF proteins display tissue specific function (Zhou et al., 2008). To evaluate 
the mechanism of NHERF1 mediated OAT4 regulation, You et al. (2009) showed that protein 
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kinase-C (PKC), which has previously been shown to inhibit NHERF1 function via 
phosphorylation, down-regulates OAT4 activity. Further studies in COS-7 cells revealed that 
NHERF1 attenuates OAT4 internalization (Zhang et al., 2010a). These studies demonstrate that 
the mechanism of NHERF1 mediated OAT4 regulation may be secondary to preventing OAT4 
internalization. 
URAT1 has also been studied in the context of NHERF mediated regulation. Similar to 
OAT4, the C-terminal PDZ ligand of URAT1 (-STQF) is required for interaction with NHERF3 
and for NHERF3 dependent functional regulation (Anzai et al., 2004). In HEK293 cells, urate 
transport was increased by NHERF3, an effect that was abolished upon deletion of the URAT1 
C-terminal PDZ ligand. Kinetic analysis revealed that this effect was due to an increase in the 
capacity of urate transport rather than a change in urate specificity for URAT1. Subsequent co-
immunoprecipitation studies showed that URAT1 co-localizes with NHERF3 at the apical brush 
border membrane in renal proximal tubule cells and the presence of the URAT1 PDZ ligand is 
required for this interaction (Anzai et al., 2004). 
Together, these studies highlight an important role for NHERF1 and NHERF3 in 
regulating OAT4 and URAT1 function. Although both transporters have been proposed to play 
important pharmacological roles, they also have been shown to mediate the renal secretion and 
reabsorption of uric acid (Graessler et al., 2006; Sakiyama et al., 2014). This implies that in 
addition to potential effects on renal drug secretion, NHERF proteins may also influence uric 
acid homeostasis and may have an underlying role in the pathophysiology of gout. 
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3. OATPs 
 
 
Five members of the OATP family harbor a class-I PDZ ligand at their C-terminus (Table 2). 
Evolutionarily, the OATPs are poorly conserved and orthologs in rodents may not exist in 
humans making findings from studies performed in animal models difficult to translate clinically. 
Although multiple studies indicate that NHERF proteins play a role in regulating rodent Oatps 
(Choi et al., 2011; Sugiura et al., 2010; Wang et al., 2005; Wang et al., 2014), there is little 
information regarding how NHERF proteins affect human OATP isoforms.  
OATP1A2 was the first identified human OATP isoform and has since been well studied and 
found to play an important role in the cellular uptake of a variety of drugs and endogenous 
substances. Recently, NHERF1 and NHERF3 were found to regulate OATP1A2 function by 
modulating protein internalization and enhancing membrane stability. The influence of NHERF1 
and NHERF3 on OATP1A2 function was assessed using HEK293 cells that co-expressed 
NHERF1 or NHERF3 (Zheng et al., 2014). Similar to studies in OATs, estrone-3-sulfate uptake 
was utilized as a surrogate for OATP1A2 function. Both NHERF1 and NHERF3 were found to 
significantly enhance E1S uptake. Overexpression of NHERF1 or NHERF3 leads to an increase 
in OATP1A2 membrane abundance and was proposed to be the underlying basis for the 
observed increase in OATP1A2 function. Subsequent studies revealed that the mechanism for 
the apparent increase in OATP1A2 membrane abundance was due to a decrease in its 
internalization via a clathrin-dependent, but caveolin-independent, manner (Zheng et al., 2014).  
NHERF proteins may have similar effects on the other human OATPs that contain C-terminal 
PDZ ligands (Table 2). Particular attention should be given to OATP2B1 due to its established 
functional role in the intestine as an uptake transporter for several drugs including fexofenadine 
and statins. OATP2B1 also uniquely displays dual-membrane specificity, apical in enterocytes 
and basolateral in hepatocytes (Figure. 1). This may indicate that if NHERF proteins are 
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involved in regulating OATP2B1, they may do so differently in the intestine than in the liver. 
Investigating the mechanism that determines intestinal versus hepatic OATP2B1 membrane 
targeting may provide clues on how NHERF proteins, or other PDZ proteins, function in different 
tissues. 
 
4. PEPTs. 
 
 
PEPT1 and PEPT2 are restricted to apical membranes in the intestine and kidney. Recent 
evidence shows that NHERF2 and NHERF3 interact with PEPT2 and enhance transport activity 
by preserving PEPT2 membrane abundance (Boehmer et al., 2008; Kato et al., 2004; Noshiro 
et al., 2006; Sugiura et al., 2006). A preliminary screening of several drug transporters and PDZ 
proteins identified a potent interaction between PEPT2 and NHERF3 (Kato et al., 2004). Studies 
using yeast two-hybrid assays and surface plasmon resonance confirmed the interaction 
between PEPT2 and NHERF3 is mediated by the PDZ2 and PDZ3 domains (Noshiro et al., 
2006). The influence of NHERF3 on PEPT2 transport was subsequently assessed in HEK293 
cells using Gly-Sar uptake as a surrogate of PEPT2 function (Noshiro et al., 2006; Sugiura et 
al., 2006). Co-expression of NHERF3 in HEK293 cells augmented PEPT2 function and was 
associated with an increase in transport capacity. Co-expression with NHERF3 increased 
PEPT2 membrane abundance and was proposed to account for the increase in function. Tsuji 
et al. (2006) later evaluated PEPT2 by assessing Gly-Sar uptake in HEK293 cells stably 
expressing NHERF3 constructs with a mutation in the PDZ2 domain (Sugiura et al., 2006). 
Although HEK293 cells overexpressing the NHERF3 mutant displayed a decrease in Gly-Sar 
uptake compared to those overexpressed with wild-type NHERF3, the results were not 
significant (Sugiura et al., 2006). Identifying the effects of genetic polymorphisms in NHERF 
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proteins on drug transport may help clarify which drug transporters are subject to NHERF 
regulation. Revealing which PDZ domains are important for drug transporter regulation also may 
provide detail on the structural requirements of NHERF function. 
Despite similarities in structure and domain organization between NHERF1 and 
NHERF2, expression studies performed in Xenopus oocytes have shown that NHERF2, but not 
NHERF1, enhance PEPT2 membrane abundance and function. This is another example of 
NHERF target-proteins displaying differential binding affinities for NHERF isoforms. The effect 
of NHERF2 on PEPT2 was not observed upon deletion of the C-terminal PDZ ligand of PEPT2 
(-KTKL), suggesting that the PEPT2 PDZ ligand is a requirement for interaction with NHERF2 
(Boehmer et al., 2008). Why NHERF1 does not produce similar effects, despite its similarity with 
NHERF2, is uncertain. 
Collectively, these studies indicate that NHERF proteins modulate PEPT2 function and 
therefore may play important physiological and pharmacological roles in oligopeptide and 
peptide-like drug transport in the kidney. However, several questions remain regarding the 
regulation of PEPT membrane targeting. For instance, it is unclear why PEPT2 preferentially 
binds NHERF2 and NHERF3, but not NHERF1, especially considering NHERF1 and NHERF3 
are highly expressed in the kidney, where PEPT2 is also prominently expressed. A closer 
inspection of PEPT2 regulation by NHERF proteins in the kidney may reveal cooperative or 
opposing roles for NHERF1 and NHERF3. This uncertainty is an opportunity to flesh out details 
regarding regulation mediated by multiple NHERF isoforms. Alternatively, NHERFs might 
regulate PEPT transport indirectly. NHERF3 may regulate PEPT1 as described (Kato et al., 
2006). PDZ proteins, such as NHERFs, may influence drug transport indirectly by regulating 
proteins that are responsible for producing electrochemical gradients necessary for dissipative 
transport. For example, PEPT1 utilizes an inwardly directed H+ gradient that is produced by the 
Na+/H+ exchanger (NHE) to provide the driving force for substrate uptake. NHERFs may 
indirectly regulate PEPT1 by directly regulating NHE or recruiting NHE in close proximity to 
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PEPT1 to ensure an adequate H+ gradient is achieved. Discovering the nature of the functional 
coupling of PEPT1 and NHE by NHERFs, as well as differences in NHERF-dependent PEPT 
membrane targeting, may broaden our understanding of NHERF action and drug transport. 
These studies will aid in understanding how PEPTs are organized at cell membranes, and lead 
to new discoveries regarding how PDZ proteins, including NHERF proteins, interact with each 
other to perform non-redundant physiological functions in different tissues. 
 
 
B. ABC Drug Transporters 
 
 
1. MRPs 
 
 
NHERF1 and NHERF3 have been reported to regulate the membrane abundance, localization, 
and function of MRP2 (-STKF) and MRP4 (-ETAL), both of which contain a class I C-terminal 
PDZ ligand. The initial discovery that NHERF proteins interact with MRPs resulted from studies 
that focused on elucidating the cellular mechanisms responsible for multidrug resistance in 
cancer after it was found that NHERF3 is up regulated in selected tumors of epithelial origin 
(Kocher et al., 1999; Kocher et al., 1998). This prompted an investigation of potential NHERF3 
binding partners. Expression studies and yeast two-hybrid assays performed in human 
carcinomas confirmed an increase in NHERF3 mRNA and revealed that NHERF3 interacts with 
the C-terminal portion of MRP2 (Kocher et al., 1999). Later, it was revealed that MRP2 interacts 
with all four NHERF isoforms (NHERF1-4) and that phosphorylation of Ser1542 in the MRP2 
PDZ binding motif significantly enhanced binding to NHERF1 and NHERF4; the functional 
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consequence was not assessed (Hegedus et al., 2003). Because of these findings, others have 
investigated the role of intracellular kinases, such as PKC, and membrane localization of MRP2. 
For example, specific PKC-isoforms, such as conventional PKCα (cPKCα), novel PKCδ 
(nPKCδ), nPKCε, and atypical PKCζ (aPKCζ), appear to be involved in regulating hepatic MRP2 
membrane recycling at the apical/canalicular membrane (Beuers et al., 2003; Ito et al., 2005; 
Park et al., 2012; Schonhoff et al., 2008; Stross et al., 2009). It is still unclear if these PKC-
mediated phosphorylation events result from direct phosphorylation of MRP2, NHERF proteins, 
or members of the ERM family, such as radixin, known to interact with and influence MRP2 
function (Suda et al., 2014; Suda et al., 2011). Investigating phosphorylation events important 
for drug transporter regulation represents an emerging line of research that intersects with the 
physiological and pharmacological role of PDZ proteins. 
To describe further the role of NHERF1 dependent MRP2 regulation in the liver, nherf1-/- 
mice have been employed. In livers obtained from nherf1-/- mice, Mrp2 mRNA was unchanged 
but protein levels were significantly decreased compared to wild-type mice, suggesting post-
transcriptional changes in Mrp2 (Li et al., 2010). Immunofluorescent staining of Mrp2 in 
hepatocytes from nherf1-/- mice showed that although a pool of Mrp2 remained at the 
apical/canalicular membrane, the signal was noticeably weaker. Bile flow in nherf1-/- mice was 
reduced by 70%, compared to wild-type mice, with a 50% and 60% reduction in glutathione and 
glutathione-methylfluorescein biliary excretion in isolated hepatocytes. Bile acid and bilirubin 
excretion, surrogates of hepatic MRP2 function, were unchanged (Li et al., 2010). Studies 
performed in nherf1-/- provide strong evidence of the importance of NHERF1 in targeting and 
stabilizing hepatic MRP2 to the apical/canalicular membrane. In a more recent study, 
fluorescent-tagged mutant constructs were utilizing in WIF-B cells, a polarized hepatocyte cell-
line, to study localization and function of NHERF1 (Karvar et al., 2014). Fluorescence 
microscopy was used to visualize the cellular distribution of NHERF1, MRP2, and radixin. A 
point mutation in the radixin binding site of NHERF1 (F335R) as well as deletion mutations 
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(PDZ1 and PDZ2) were used to assess NHERF1 membrane association and a 5-
chloromethylfluorescein diacetate (CMFDA) assay was used to characterize MRP2 function. It 
was later confirmed that only overexpression with the radixin binding site mutant (F335R) and 
the PDZ1 deletion mutant resulted in decreased NHERF1 membrane association and MRP2 
function (Karvar et al., 2014). These results support that the functional importance of NHERF1 
depends on its interaction with MRP2 and the PDZ1 domain and demonstrate that NHERF1 is 
important for the distributional dynamics of MRP2 in the liver. Although NHERF3 was the initial 
NHERF isoform identified to interact with MRP2 (Kocher et al., 1999), subsequent studies 
performed in kidney proximal tubule cells of nherf3-/- mice revealed no change in expression or 
cellular distribution of Mrp2 (Kocher et al., 2003). This indicates that NHERF3 is not involved in 
MRP2 membrane targeting. Alternatively, functional compensation by other PDZ proteins or 
cytoplasmic adapters may preserve MRP2 membrane abundance in the absence of NHERF3 
and thus be confounding these results. 
The anti-viral drug adefovir is an established MRP4 probe substrate and is often used as 
a surrogate of MRP4 function. As noted earlier, MRP4 is critical for the renal elimination of 
adefovir (Imaoka et al., 2007). NHERF1 and NHERF3 also regulate MRP4 membrane 
localization and function; however, they appear to have opposing roles, as down regulation of 
NHERF1 increases MRP4 function, whereas NHERF3 stabilizes MRP4 at apical membranes 
and increases function (Hoque and Cole, 2008; Hoque et al., 2009; Park et al., 2014). Knock 
down of NHERF1 by small interfering RNA (siRNA) in HeLa cells increases MRP4 membrane 
abundance and reduces cellular accumulation of the MRP4 probe substrates, 6-mercaptopurine 
and 9-[2-(phosphonylmethoxy) ethyl]-adenine (Hoque and Cole, 2008). The authors attributed 
these results to a decrease in MRP4 internalization mediated by NHERF1. It was later 
demonstrated that MRP4 localizes to either apical or basolateral membranes depending on the 
cell type and the degree of NHERF1 expression (Hoque et al., 2009). This study found that 
MRP4 localizes to basolateral membranes in MDCKI cells, where NHERF1 expression is low, 
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whereas MRP4 localizes to apical membranes in LLC-PK1 cells, which express a higher 
amount of NHERF1 (Hoque et al., 2009). Although these studies provide proof-of-principle, in-
vitro cell systems are limited and may not represent the endogenous role(s) of NHERF proteins 
and drug transporter regulation. Further, PDZ regulation of drug transporters are not likely to 
depend on a single PDZ isoform but rather multiple isoforms, as well as on members of the 
ERM family. For these reasons, extrapolating these data to in vivo systems will advance our 
understanding of PDZ regulatory processes. 
In contrast to NHERF1, NHERF3 is critical for MRP4 dependent efflux in the kidney. The 
role of NHERF3 on MRP4 membrane targeting and function was assessed in an elegantly 
conducted study using nherf3-/- mice and HEK293 cells, (Park et al., 2014). MRP4 protein 
expression, membrane abundance, and function decreased in nherf3-/- mice compared to wild-
type mice. A pharmacokinetic study evaluated the role of NHERF3 on MRP4 dependent renal 
drug elimination (Park et al., 2014). Mice were administered an intravenous injection of [3H]-
adefovir, an established prototype MRP4 probe substrate that undergoes negligible metabolism 
and is predominately eliminated via the kidney. Plasma clearance of [3H]-adefovir was 
significantly decreased in nherf3-/- mice compared to wild type mice. This result was 
accompanied by a significant increase in the [3H]-adefovir concentration area under the curve 
(AUC0-inf), which is reflective of the systemic exposure of [3H]-adefovir. Further, the 
concentration of [3H]-adefovir in kidneys was significantly higher in nherf3-/- mice compared to 
wild-type mice suggesting impaired MRP4 mediated efflux from renal proximal tubules (Park et 
al., 2014). Collectively, these pharmacokinetic changes suggest that NHERF3 plays a crucial 
role in MRP4 dependent renal drug elimination as a regulator of MRP4 apical membrane 
insertion in proximal tubule epithelial cells, and thus an indirect contributor to drug clearance via 
the kidney. Immunoprecipitation assays using transfected HEK293 cells revealed that the 
interaction between NHERF3 and MRP4 is mediated by the C-terminal portion of MRP4 (-ETAL) 
and the PDZ1 domain of NHERF3 (Park et al., 2014). When co-expressed in HEK293 cells, 
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surface biotinylation and internalization assays revealed that NHERF3 increases MRP4 
membrane stability and reduces MRP4 internalization (Park et al., 2014). Pharmacokinetic 
studies that utilize nherf1-/- and nherf3-/- mice represent the next stage in translating the 
pharmacological significance of NHERF proteins and drug transport. 
Several questions remain regarding how NHERF1 and NHERF3 affect MRP4 function 
and why they seemingly exhibit opposite actions. It is unclear why MRP4 localizes to basolateral 
membranes in hepatocytes rather than the apical membrane, as it does in renal proximal 
tubules. Although NHERF proteins are likely involved in MRP4 membrane organization and 
function, members of the ERM family may also direct MRP4 targeting, as they do with MRP2. 
Investigating the interaction between NHERF proteins, MRP2, MRP4, and members of the ERM 
family may provide additional details regarding tissue specific mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  52 
V. PDZ PROTEINS AND DRUG ACTION IN DISEASE STATES 
 
 
 
A. Cancer.  
 
 
The ABC superfamily of drug transporters is well known in oncology for their role in conferring 
multidrug resistance (MDR) (Gottesman et al., 2002). ABC transporters actively efflux a broad 
array of chemotherapeutic agents such as taxanes, camptothecins, and platinum agents, thus 
contributing to decreased intracellular drug accumulation in tumor cells and ultimately failure of 
chemotherapy (Gottesman et al., 2002). Pgp (MDR1), MRP1 (ABCC1), and BCRP (ABCG2), 
the ABC superfamily, play important roles in MDR (Doyle et al., 1998; Kunicka and Soucek, 
2014; Wu et al., 2014). Overexpression of these transporters is well documented in many types 
of cancer, and considered to be the underlying mechanism for chemoresistance attributable to 
ABC drug efflux in tumors (Szakacs et al., 2006; Teodori et al., 2006; Wu et al., 2014). 
Substrate-induced induction is one mechanism involved in the upregulation of ABC drug 
transporters, where chemotherapeutic drugs enhance chemoresistance through nuclear 
receptors involved in the transcriptional expression of efflux drug transporters (Chen, 2010; 
Herraez et al., 2012; Manceau et al., 2012; Oda et al., 2013). For example, the pregnane X 
receptor (PXR) is a nuclear receptor that binds promiscuously with many structurally diverse 
ligands, including anti-cancer drugs such as paclitaxel (Harmsen et al., 2009; Harmsen et al., 
2010). The expression of PXR has been characterized in many cancers where it is thought to be 
involved in resistance to chemotherapy. Upon ligand activation, PXR forms a heterodimer with 
other nuclear receptors, such as the retinoid X receptor, and induces the expression of target 
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genes involved in drug resistance. It has been clearly demonstrated that PXR directly regulates 
Pgp expression (Harmsen et al., 2010). To address the problem of MDR in cancer, novel host- 
and tumor-mediated pathways continue to be explored in an effort to identify potential new 
therapeutic targets. 
The clinical contribution to MDR from other drug transporters remains uncertain. 
However, in an evaluation of ABC drug transporters in a panel of tumor cell lines from the US 
National Cancer Institute, over half of the members that comprise the ABC drug transporter 
family have been implicated as playing a role in conferring MDR, suggesting multiple drug 
transporters are likely involved (Szakacs et al., 2004). As a means to combat MDR in cancer 
patients, targeting ABC drug transporters through pharmacological inhibition has been 
attempted for several years but with poor results (Karthikeyan and Hoti, 2015; Turk and 
Szakacs, 2009). Due to their clinical contribution to MDR, studies aimed at understanding the 
regulatory mechanisms of transporters focus heavily on changes in gene and protein 
expression. Studies that investigate post-translational modification of drug transporters in 
cancer remain an area of research that is underrepresented. Future studies aimed at expanding 
our knowledge of drug transporter regulation in cancer outside the realm of transcriptional 
regulation are warranted. 
The NHERF proteins, particularly NHERF1, have been implicated in different types of 
cancers. Although its role as a tumor suppressor and/or oncogenic protein remains 
controversial, overexpression of NHERF1 in several cancers, such as breast cancer, 
schwannoma, and hepatocellular carcinoma has been described (Cardone et al., 2007; 
Fraenzer et al., 2003; Shibata et al., 2003; Stemmer-Rachamimov et al., 2001). In addition, 
tumor stage, metastatic progression, poor prognosis, and estrogen receptor status are 
significantly associated with NHERF1 overexpression (Cardone et al., 2007; Song et al., 2007). 
Further, NHERF1 upregulation in conditions of serum deprivation and hypoxia suggest that 
NHERF1 function may increase in a tumor microenvironment (Cardone et al., 2007). Although 
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NHERF1 expression increases in human cancer, its cellular distribution appears to shift from the 
plasma membrane to nuclear and cytoplasmic regions (Cardone et al., 2007; Fraenzer et al., 
2003; Stemmer-Rachamimov et al., 2001). The functional consequences of the observed shift in 
the cellular distribution of NHERF1 in cancer continue to be investigated. 
The mechanisms of MDR in cancer are likely multifactorial. In addition to alterations in 
transcriptional expression, post-translational modification of drug transporters may also be 
affected. The reported changes in NHERF1 expression in cancer combined with the newly 
described role of NHERF1 in drug transporter function, underscores NHERF1 as an attractive 
and novel MDR target that is worthy of investigation. A critical evaluation of the role of NHERF1, 
as well as other NHERF isoforms, and drug transporter function in cancer may offer mechanistic 
insight into chemoresistance. Overexpression of select drug transporters, such as those 
believed to play major roles in cancer (Pgp, MRP1, and BCRP), may represent only one of 
several mechanisms that contribute to MDR. Although not considered to confer significantly to 
MDR, ABC drug transporters that contain Class-I PDZ ligands, such as MRP2 and MRP4, are 
implicated in chemoresistance (Kool et al., 1997; Zhang et al., 2010b). Therefore, the observed 
reduction in drug action may be partially attributable to altered membrane targeting and/or 
abundance of drug transporters involved in efflux of chemotherapeutic agents. Faulty 
membrane targeting may not result in observable changes in mRNA or protein expression of 
drug transporters in cancer and therefore those transporters subject to NHERF regulation may 
be overlooked despite their potential involvement in conferring resistance. Turning attention to 
NHERF1 as a mediator of drug transporter regulation in cancer may lead to a more complete 
understanding of MDR while also highlighting NHERF1 as a potential new target. 
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B. Chronic Kidney Disease.   
 
 
A well-known consequence of chronic kidney disease (CKD) is reduced renal drug clearance. 
Dosing guidelines have been developed for drugs that undergo renal elimination, where doses 
are adjusted according to some measure of kidney function (i.e., creatinine clearance or 
glomerular filtration rate) based on the premise that renal clearance declines in proportion to 
kidney function (Nielsen et al., 2014). Despite the development of renal dosing guidelines, 
patients with CKD experience high rates of adverse drug events (Zaidenstein et al., 2002). 
However, both renal and extra-renal drug clearance mediated by key drug transporters is 
altered in patients with CKD (Nolin et al., 2009). This undoubtedly contributes to the high 
variability in drug response and the increased frequency of adverse drug events observed in 
CKD patients (Bates et al., 1999; Matzke and Frye, 1997; Nolin and Unruh, 2010; Zaidenstein et 
al., 2002). Changes in drug transporter gene and protein expression in both renal and extra-
renal tissues do not consistently correlate with the expected changes in transporter function in 
the setting of CKD. For instance, intestinal Pgp function is reduced ex vivo in the intestine of 
5/6th nephrectomized rats, an experimental model of CKD (Veau et al., 2001). Interestingly, no 
change in Pgp mRNA or protein expression was observed, indicating that changes in 
transcriptional expression could not explain the reduction in function. Later, others confirmed 
and extended these results to other transporters. In 5/6th nephrectomized rats, a significant 
decrease in Pgp, Mrp2, and Mrp3 protein expression was observed with no change in mRNA 
(Naud et al., 2007). These discrepancies are not limited to the intestine. Additional studies 
utilizing the same experimental animal model of CKD show that several hepatic and renal drug 
transporters, such as members from the Oatp, Oat, Oct, Pgp, and Mrp families, also display 
changes in expression that do not correlate with function (Ji et al., 2002; Laouari et al., 2001; 
Naud et al., 2008; Tsujimoto et al., 2008). However, data across studies yield highly variable 
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and inconsistent results, which makes interpretation difficult. Further, despite these important 
findings, there is currently no clear mechanism as to the cause. These discrepancies and lack of 
a definitive mechanism for changes in transporter function in CKD limits the extrapolation of 
these data into the clinical setting.  
To date, studies aimed at evaluating changes in gene and protein expression alone in 
CKD have not reconciled this disparity. Many studies attribute uremic toxins, metabolic 
byproducts that accumulate in uremia, as a major cause of reduced drug transporter function in 
CKD (Barreto et al., 2014; Masereeuw et al., 2014). Uremic toxins are believed to competitively 
inhibit drug transport and to down regulate transporter expression (Reyes and Benet, 2011; 
Sato et al., 2014). However, uremic toxins do not begin to accumulate until end-stage renal 
disease (ESRD) and therefore may only explain changes in drug transporter function in patients 
with ESRD. Moreover, hundreds, if not thousands of uremic toxins may exist (Masereeuw et al., 
2014; Massy, 2014; Vanholder et al., 2003). Determining which toxin(s) have the greatest 
impact on transporter function has also proved difficult. The mechanisms responsible for 
reduced drug transporter function may be more complex and begin in earlier stages of CKD, 
well before reduced kidney function limits uremic toxin elimination. Novel mechanistic 
hypotheses that address altered drug transporter function in CKD are needed to advance our 
understanding of this field and ultimately develop dosing strategies to prevent adverse events in 
this patient population. 
CKD represents a disease state for which exploration of NHERF dependent drug 
transporter regulation may provide novel insights into altered transporter function (Figure. 5). 
How drug transporter function changes in CKD from the standpoint of NHERF dependent 
transport has yet to be investigated. This is likely because only recently has research in drug 
transporter membrane targeting gained interest. The NHERF family is abundantly expressed in 
the intestine, liver, and kidney, tissues that also highly express transporters. To date, there are 
no data on changes in NHERF function in CKD. Consideration should be given to understanding  
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Figure 5 
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how NHERF function may change over the course of CKD and the implications on drug 
 
transport. 
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VI. CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
The functional regulation of drug transporters by the NHERF family continues to capture 
the attention of those who investigate the underlying mechanisms that govern pharmacokinetics 
and pharmacodynamics. This relatively novel understanding of NHERF is still in its infancy, as 
several questions remain surrounding the NHERF family and regulation of drug transport. 
Future studies in this area should focus on addressing 1) the NHERF isoforms affecting drug 
transport and which transporters are the most susceptible to regulation by NHERF; 2) the 
different mechanisms of NHERF-directed membrane targeting depending on tissue type; 3) the 
functional importance of NHERF dimerization and cooperativity as it relates to drug transport 4) 
the role of the ERM family in NHERF/drug transporter interactions; and 5) the role of NHERF 
proteins in MDR in cancer and altered drug transport function in CKD. Additional 
pharmacokinetic studies using specific phenotypic probe substrates of drug transport performed 
in nherf1-/- and nherf3-/- mice would provide an excellent model to begin addressing these gaps 
in our understanding. However, data performed in mouse models eventually must be translated 
to humans. The inability to assess NHERF non-invasively in humans represents an important 
limitation to this work. However, mutations in the human NHERF1 (SLC9A3R1) gene do exist 
(Karim et al., 2008). Clinical pharmacokinetic studies performed in patients who carry 
polymorphisms in the NHERF1 (SLC9A3R1) gene, may provide a means to address this 
limitation. 
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